Should I buy Edwards Lifesciences (EW) stock or is it too late?
⭐ The most reliable of them, either direction: JP Morgan — 67% of its targets hit on this sector (355 calls tested). It aims for $105 (+17 %), call made on July 25, 2026, maturing on July 25, 2027 (34 d ago).
Firm-by-firm track record on Edwards Lifesciences
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Stifel | 88 % | +24.1 % | 16 | $110 +22% |
| Canaccord Genuity | 56 % | +15.0 % | 16 | $85 -6% |
| Wells Fargo | 71 % | +11.3 % | 17 | $100 +11% |
| Piper Sandler | 62 % | +5.7 % | 16 | $101 +12% |
| Barclays | 62 % | +2.8 % | 13 | $110 +22% |
| Goldman Sachs | 38 % | -1.6 % | 8 | $95 +6% |
| RBC Capital | 33 % | -3.4 % | 21 | $110 +22% |
| Mizuho | 56 % | -4.6 % | 9 | $105 +17% |
✅ Reasons to believe
- 77% of analysts rate it a buy (Buy consensus, 13 ratings) — a sign of market conviction.
- Median price target $104, i.e. +16% from the current price ($90).
- The most reliable firm on EW, Evercore ISI Group (100% hit rate, 2 scored calls), targets $100 (call made on July 6, 2026, maturing on July 6, 2027) (+11%) in its most recent call, and $92 (call made on April 6, 2026, maturing on April 6, 2027) (+2%) in the one coming due soonest.
- 7 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 13 ratings, 3 are neutral.
- High valuation (P/E ~54): strong growth is already "priced in", leaving little room for error.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on EW
Median target $104 (+16%) · 13 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Edwards Lifesciences now?
We won't decide for you. The facts: 77% of analysts rate it a buy, median target $104 (+16%), and Evercore ISI Group (most reliable on EW, 100%) targets $100. Weigh that against valuation (P/E ~54). This is not personalized advice.
Is it too late to invest in Edwards Lifesciences?
Not according to analysts: the median target ($104) is still +16% above the current price ($90) (most reliable on EW: Evercore ISI Group, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Edwards Lifesciences still worth investing in?
It depends on the gap between the price ($90) and its estimated value: analysts target $104 on median (+16%), with 77% buys (most reliable on EW: Evercore ISI Group, 100%). Cross-check with their real reliability on EW and the cautions above. Information, not advice.
What's the main risk in buying EW?
The consensus is not unanimous: of 13 ratings, 3 are neutral.
→ Go deeper: the full Edwards Lifesciences profile (consensus, analyst reliability, price target, performance).